- Home
- BCDA vs SYNX Comparison
BCDA vs SYNX Comparison
Compare BCDA & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SYNX
- Stock Information
- Founded
- BCDA N/A
- SYNX 2005
- Country
- BCDA United States
- SYNX Israel
- Employees
- BCDA N/A
- SYNX N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SYNX
- Sector
- BCDA Health Care
- SYNX
- Exchange
- BCDA Nasdaq
- SYNX Nasdaq
- Market Cap
- BCDA 11.3M
- SYNX 10.2M
- IPO Year
- BCDA N/A
- SYNX 2024
- Fundamental
- Price
- BCDA $1.35
- SYNX $1.66
- Analyst Decision
- BCDA Strong Buy
- SYNX
- Analyst Count
- BCDA 1
- SYNX 0
- Target Price
- BCDA $25.00
- SYNX N/A
- AVG Volume (30 Days)
- BCDA 1.6M
- SYNX 110.3K
- Earning Date
- BCDA 11-12-2025
- SYNX 09-26-2025
- Dividend Yield
- BCDA N/A
- SYNX N/A
- EPS Growth
- BCDA N/A
- SYNX N/A
- EPS
- BCDA N/A
- SYNX N/A
- Revenue
- BCDA N/A
- SYNX $6,003,000.00
- Revenue This Year
- BCDA N/A
- SYNX $32.35
- Revenue Next Year
- BCDA N/A
- SYNX N/A
- P/E Ratio
- BCDA N/A
- SYNX N/A
- Revenue Growth
- BCDA N/A
- SYNX N/A
- 52 Week Low
- BCDA $1.00
- SYNX $1.37
- 52 Week High
- BCDA $3.20
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- BCDA 38.89
- SYNX 56.55
- Support Level
- BCDA $1.27
- SYNX $1.37
- Resistance Level
- BCDA $1.42
- SYNX $1.74
- Average True Range (ATR)
- BCDA 0.11
- SYNX 0.09
- MACD
- BCDA 0.01
- SYNX 0.02
- Stochastic Oscillator
- BCDA 70.00
- SYNX 76.01
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.